The estimated Net Worth of Krish S Krishnan is at least 373 百万$ dollars as of 11 June 2024. Mr Krishnan owns over 50,000 units of Krystal Biotech Inc stock worth over 303,330,083$ and over the last 11 years he sold KRYS stock worth over 68,394,506$. In addition, he makes 1,008,932$ as Founder、 Chairman、 Pres & CEO at Krystal Biotech Inc.
Mr has made over 29 trades of the Krystal Biotech Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of KRYS stock worth 8,788,000$ on 11 June 2024.
The largest trade he's ever made was selling 100,000 units of Krystal Biotech Inc stock on 10 December 2021 worth over 7,050,000$. On average, Mr trades about 33,479 units every 102 days since 2014. As of 11 June 2024 he still owns at least 1,525,882 units of Krystal Biotech Inc stock.
You can see the complete history of Mr Krishnan stock trades at the bottom of the page.
Krish S. Krishnan M.B.A., M.S. is the Founder, Chairman, Pres & CEO at Krystal Biotech Inc.
As the Founder、 Chairman、 Pres & CEO of Krystal Biotech Inc, the total compensation of Mr S at Krystal Biotech Inc is 1,008,932$. There are no executives at Krystal Biotech Inc getting paid more.
Mr S is 56, he's been the Founder、 Chairman、 Pres & CEO of Krystal Biotech Inc since . There are no older and 10 younger executives at Krystal Biotech Inc.
Krish's mailing address filed with the SEC is C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203.
Over the last 7 years, insiders at Krystal Biotech Inc have traded over 166,816,526$ worth of Krystal Biotech Inc stock and bought 536,800 units worth 5,949,380$ . The most active insiders traders include Daniel Janney、Dino A Rossi、Krish S Krishnan. On average, Krystal Biotech Inc executives and independent directors trade stock every 40 days with the average trade being worth of 8,043,043$. The most recent stock trade was executed by Suma Krishnan on 11 June 2024, trading 50,000 units of KRYS stock currently worth 8,788,000$.
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
Krystal Biotech Inc executives and other stock owners filed with the SEC include: